Good MorningEquity markets tried to rebound on Thursday, but the move was weak and short-lived. The S&P 500 gained about a half percent at the session's high but closed the day with a loss of 0.35%. The move may turn into a deeper rout today following the NFP report. If it aligns with labor data released this week, it will reaffirm the idea that the FOMC will keep interest rates higher for longer. In this scenario, the FOMC is on track to cut rates in 2023, but when and why are yet to be seen. As it is, the first cuts aren't likely until later in the year.
Next week starts peak earnings season, but don't get too excited yet. The reports will come out in dribbles until Friday, when reports from the big banks are due. The general expectation is that banks generate solid profits due to higher interest rates and can sustain capital returns. The question is how the consumer is holding up. If the banks reveal a weakened or weakening consumer, the sell-off in equities could gain momentum regardless of bank earnings.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Finance | |
Coinbase Global Inc. (NASDAQ: COIN) is the largest publicly traded cryptocurrency exchange in the U.S. It is arguably the most trusted and stable exchange due to its regulatory transparency and liquidity. As a member of the financial services sector, Coinbase is considered the crypto exchange of c... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Industrials | |
The aviation sector, marked by its susceptibility to economic fluctuations and global events, holds both promise and caution for investors. As the dust settles from the turbulence brought about by the COVID-19 pandemic, investors are eyeing American Airlines with a critical lens, evaluating whethe... Read the Full Story |
|
Consumer Discretionary | |
You've probably heard of growth stocks before, but what is a growth stock mutual fund? When buying individual stocks, there's always the risk that a bad earnings report could significantly hurt the share price.
But that risk is mitigated when a basket of stocks is held, and growth stock mutual f... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | |
"Is Delta Air Lines stock a buy?" is a question frequently asked by investors.
Delta Air Lines is one of the world's largest airlines, and its stock has been relatively volatile in recent months. The company has benefited from a strong recovery in air travel, and its financial results have been ... Read the Full Story |
|
Markets | |
If you're like most investors, retirement is one of your major financial goals. However, the road toward retirement can often seem overwhelming and confusing — especially regarding the many types of retirement accounts you can use to invest. An individual retirement account (IRA) is a tax-ad... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
The United States economy has pumped out two consecutive quarters of real GDP growth because it is still very positive even after you adjust for inflation. This is good for stocks but better for certain stocks, such as those exposed to the consumer discretionary cycle. Speaking of which, here's wh... Read the Full Story |
|
Markets | |
The stock market is like a bustling stage, and on the first trading day of the year, one performer stole the show while others struggled to keep up.
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. In sta... Read the Full Story |
|
Technology | |
The S&P 500 and other major indexes are getting off to a slow start to kick off the new year. Some of 2023’s leading stocks including Tesla Inc. (NASDAQ: TSLA), Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), Micron Technology Inc. (NASDAQ: MU), Apple Inc. (NASDAQ: AAPL) and Meta Platf... Read the Full Story |
|
Consumer Staples | |
Investors looking for value and yield have no further to look than the Consumer Staples sector. The sector corrected sharply in the second half of 2023 and now, even after rebounding smartly, provides a value relative to historical norms and the pandemic bubble. The takeaway is that the sector as ... Read the Full Story |
|
Markets | |
Walgreens Boots Alliance (NYSE: WBA) is the ugliest dog of them all. This Dow stock fell 31% for the year, making it the worst-performing member of the index. The move put the yield near 8% and the value as good, making it an attractive play for value-minded income and Dogs of the Dow investors. H... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. | | View Today's Stock Pick |
|
